In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 181 to 190 of 303

TitleTypeExpected publication date
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Technology appraisal guidanceTBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]Technology appraisal guidanceTBC
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]Technology appraisal guidanceTBC
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423Technology appraisal guidance
Omburtamab for treating relapsed neuroblastoma [ID1664]Technology appraisal guidanceTBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]Technology appraisal guidanceTBC
OrganOx metra for liver transplant [ID5116]Technology appraisal guidanceTBC
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]Technology appraisal guidanceTBC
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]Technology appraisal guidance
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All